

## CIRM Funded Clinical Trials

### Anti-HIV duoCAR-T cell therapy for HIV infection

<b>Disease Area:</b>	HIV/AIDS
<b>Investigator:</b>	Steven Deeks
<b>Institution:</b>	University of California, San Francisco
<b>CIRM Grant:</b>	CLIN2-12090 (Pre-Active)
<b>Award Value:</b>	\$8,970,732
<b>Trial Sponsor:</b>	University of California, San Francisco
<b>Trial Stage:</b>	Phase 1/2
<b>Trial Status:</b>	Launching
<b>Targeted Enrollment:</b>	N/A



Steven Deeks

#### Details:

The University of California San Francisco (UCSF) is conducting a clinical trial that modifies a patient's own immune cells in order to treat and potentially cure HIV.

Current treatment of HIV involves the use of long-term antiretroviral therapy (ART). However, many people are not able to access and adhere to long-term ART.

The team will take a patient's blood and extract T cells, a type of immune cell. The T cells are then genetically modified to express two different chimeric antigen receptors (CAR), which enable the newly created duoCAR-T cells to recognize and destroy HIV infected cells. The modified T cells are then reintroduced back into the patient.

The goal of this one time therapy is to act as a long-term control of HIV with patients no longer needing to take ART, in effect a form of HIV cure. This approach would also address the needs of those who are not able to respond to current approaches, which is estimated to be 50% of those affected by HIV globally.

#### Design:

This is a Phase I/IIA clinical trial.

#### Goal:

To evaluate safety and tolerability.